Drugs / Repository Corticotropin Injection
Repository Corticotropin Injection
also known as
H.P. Acthar Gel (repository corticotropin injection)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01601236 | May 2012 → Jan 2016 | diabetic kidney disease | Mallinckrodt | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Mallinckrodt | Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research gcs-web.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Repository Corticotropin Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01601236 ↗ |
| Known as | H.P. Acthar Gel (repository corticotropin injection) | “H.P. Acthar Gel (repository corticotropin injection)” NCT01601236 ↗ |
| Route | Subcutaneous | “is administered via daily SC injection for 36 weeks” NCT01601236 ↗ |